1. Clinical Need
Lung cancer is the leading cause of cancer death in the United States, with an estimated 226,650 new diagnoses and 124,730 deaths projected annually (American Cancer Society, Cancer Statistics, 2025). The five-year survival rate for localized lung cancer exceeds 60%, but only 26% of cases are diagnosed at this stage. Expansion of low-dose computed tomography (LDCT) screening under USPSTF guidelines has increased detection of small peripheral pulmonary lesions (PPLs), many of which are indeterminate nodules requiring tissue diagnosis to distinguish malignancy from benign disease.
Peripheral pulmonary lesions located in the outer third of the lung, beyond the reach of conventional bronchoscopes, present a diagnostic bottleneck. Traditional flexible bronchoscopy achieves diagnostic yields of only 14 to 36% for lesions under 20mm. Electromagnetic navigation bronchoscopy (ENB) improved yields to 53 to 73%, but suffers from CT-to-body divergence errors that accumulate as the catheter advances distally. CT-guided transthoracic needle biopsy achieves yields of 85 to 95% but carries a pneumothorax rate of 15 to 43% and is contraindicated in patients with emphysema, anticoagulation, or bilateral disease.
Robotic-assisted bronchoscopy (RAB) platforms have improved peripheral access substantially. Three FDA-cleared systems exist: Ion (Intuitive Surgical), Monarch (Johnson & Johnson, via Auris Health), and Galaxy (Noah Medical). These platforms use shape-sensing fiber optics or electromagnetic tracking to guide ultra-thin catheters through the bronchial tree, achieving diagnostic yields of 80 to 86% in recent multicenter studies. In a meta-analysis of 12 studies with 838 nodules, the pooled diagnostic yield of robotic bronchoscopy was 81.9%, with a complication rate of 3.0%.
Despite these advances, all three commercial platforms remain fully physician-controlled. A trained interventional pulmonologist must manually navigate the catheter through each airway bifurcation, interpret bronchoscopic video in real time, and make continuous steering decisions across 10 to 23 branching generations. This creates two compounding constraints. First, a physician expertise bottleneck: the number of trained interventional pulmonologists limits procedural throughput, particularly in community hospitals and underserved regions where LDCT screening detects nodules but specialist navigation capability is absent. Second, operator variability: diagnostic yield varies significantly between experienced and novice operators, with less experienced bronchoscopists achieving yields 15 to 20 percentage points lower than experts for the same lesion characteristics.
The unmet clinical need is an autonomous navigation layer that guides the robotic bronchoscope through the bronchial tree to a target lesion using reinforcement learning, reducing dependence on physician steering expertise while maintaining or exceeding current diagnostic yields. This capability would function as a software module deployed on existing FDA-cleared hardware, preserving the physician’s role in biopsy and clinical decision-making while automating the navigation task that constitutes 60 to 80% of procedural time.
2. State of the Art
Five independent research trajectories have converged toward autonomous bronchoscope navigation since 2024, each validating a distinct approach but none yet integrated into a commercial product.
AI co-pilot with live animal validation
Zhang et al. published in Nature Communications (2024; DOI: 10.1038/s41467-023-44385-7) the first AI co-pilot bronchoscope robot validated in live porcine models. The system combines a user-friendly, plug-and-play catheter with AI-driven steering assistance, enabling novice operators to conduct lung examinations accessing bronchi beyond the fifth generation in average adult patients. The platform demonstrated that AI-augmented navigation can bridge the expertise gap between specialist and non-specialist operators in a clinically relevant large-animal model.
Remote AI-guided foreign body retrieval over 5G
Liu et al. published in Science Robotics (2025; DOI: 10.1126/scirobotics.adt5338) a cost-effective robotic bronchoscope (under $5,000, under 2 kg) capable of CT-free, AI-driven foreign body search and physician-collaborated removal over long distances via 5G communication. In a landmark demonstration, a physician in Hangzhou successfully retrieved a foreign body from a live pig located 1,500 km away in Chengdu. The AI system autonomously searched the bronchial tree using a 3.3mm catheter with 1mm biopsy forceps, while the physician performed the extraction. This established that AI-driven bronchoscopic search is feasible without preoperative CT planning, using only real-time visual feedback.
Multimodal RL for fifth-generation autonomous navigation
Zhao et al. presented BronchoCopilot at IROS (2024; DOI: 10.1109/IROS58592.2024.10802152), a multimodal reinforcement learning agent integrating bronchoscope camera images and estimated robot poses. The system achieved a success rate of approximately 90% in reaching fifth-generation airways in a realistic simulation environment, demonstrating that multimodal RL can learn effective navigation policies from endoscopic video without external tracking hardware.
Pure-vision navigation to eighth-generation airways
Wu et al. (2026; arXiv:2603.07909) from Shanghai Jiao Tong University and Shanghai Chest Hospital developed a hierarchical long-short agent framework for pure-vision bronchoscopy autonomy. A short-term reactive agent handles continuous motion control while a long-term strategic agent provides decision support at anatomically ambiguous bifurcation points. When their recommendations conflict, a world-model critic selects the optimal action. The system reached all planned segmental targets in a high-fidelity phantom, maintained 80% success to the eighth generation in ex vivo porcine lungs, and achieved in vivo navigation performance comparable to an expert bronchoscopist.
Conditional autonomy for transbronchial interventions
Banach et al. published in IEEE Transactions on Biomedical Engineering (2025; DOI: 10.1109/TBME.2025.3565915) a conditional autonomy framework where operators specify the next target airway at bifurcation points and the autonomous system navigates and aligns the bronchoscope using only monocular bronchoscopic video. This architecture preserves physician oversight at the strategic level while automating the continuous low-level catheter manipulation that requires the most dexterity and fatigue resistance.
The gap between these demonstrated capabilities and a deployable product is threefold: (a) no existing research system has been integrated with FDA-cleared robotic bronchoscopy hardware; (b) no system has been validated in a clinical trial with human patients; and (c) no manufacturing pathway exists for a productized autonomous navigation module.
3. Foundational Research
Zhang J, Liu L, Xiang P, Fang Q, Nie X, Ma H, Hu J, Xiong R, Wang Y, Lu H. (2024). “AI co-pilot bronchoscope robot.” Nature Communications, 15(1):241. DOI: 10.1038/s41467-023-44385-7.
Developed at Zhejiang University in collaboration with the First Affiliated Hospital of Zhejiang University School of Medicine. Integrates a custom plug-and-play robotic catheter with an AI co-pilot that assists navigation decisions. Validated in live porcine models with multiple operators of varying experience levels. AI assistance enabled novice operators to access bronchi beyond the fifth generation, a level typically requiring specialist training. First published demonstration that AI-assisted bronchoscopic navigation is safe and effective in vivo in a top-tier journal.
Liu L, Zhang J, Wang F, Yu J, Cui Y, Li Z, Hu J, Xiong R, Lu H, Wang Y. (2025). “AI search, physician removal: Bronchoscopy robot bridges collaboration in foreign body aspiration.” Science Robotics, 10(104):eadt5338. DOI: 10.1126/scirobotics.adt5338.
Developed at Zhejiang University. A portable (under 2 kg), low-cost (under $5,000) robotic bronchoscope platform with a 3.3mm catheter and 1mm biopsy forceps. The AI system autonomously navigates the bronchial tree to locate foreign bodies without preoperative CT, using real-time endoscopic video as the sole input. Demonstrated 5G remote operation at 1,500 km (Hangzhou to Chengdu) in a live porcine model. Validated CT-free autonomous bronchoscopic navigation and demonstrated that latency-tolerant AI navigation can extend specialist capability to any location with network connectivity.
Zhao J, Chen H, Tian Q, Chen J, Yang B, Liu H. (2024). “BronchoCopilot: Towards Autonomous Robotic Bronchoscopy via Multimodal Reinforcement Learning.” IEEE/RSJ International Conference on Intelligent Robots and Systems (IROS), pp. 6923–6930. DOI: 10.1109/IROS58592.2024.10802152.
Developed at Harbin Institute of Technology. Integrates endoscopic camera images and estimated robot poses as multimodal input to an RL agent. Auxiliary reconstruction tasks compress multimodal data, and attention mechanisms produce an efficient latent representation for the RL policy. Achieved approximately 90% success rate navigating to fifth-generation airways in a realistic simulation environment. Established that multimodal RL, combining visual and proprioceptive feedback, outperforms single-modality approaches for bronchoscopic navigation.
Wu J, Luo M, Xie F, et al. (2026). “Long-Short Term Agents for Pure-Vision Bronchoscopy Robotic Autonomy.” arXiv:2603.07909.
Developed at Shanghai Jiao Tong University and Shanghai Chest Hospital. A hierarchical imitation-learning framework using only endoscopic video and preoperative CT, with no external localization hardware. Short-term reactive agent provides continuous low-latency motion control; long-term strategic agent provides decision support at anatomically ambiguous bifurcation points; world-model critic arbitrates conflicts by predicting future visual states. Evaluated in a high-fidelity airway phantom (all segmental targets reached), three ex vivo porcine lungs (80% success to the eighth generation), and a live porcine model (navigation performance comparable to expert bronchoscopist). The deepest autonomous penetration of the bronchial tree published to date.
Banach A, Masaki F, Athanasiou L, King F, Kharroubi H, Tfayli B, Tsukada H, Colson Y, Hata N. (2025). “Conditional Autonomy in Robot-Assisted Transbronchial Interventions.” IEEE Transactions on Biomedical Engineering, 72(11):3256–3267. DOI: 10.1109/TBME.2025.3565915.
Developed at Harvard Medical School and Brigham and Women’s Hospital. Separates high-level strategic decisions (which airway to enter) from low-level catheter manipulation (how to navigate and align within an airway segment). Physician specifies target airways at bifurcation points; autonomous system navigates and aligns the bronchoscope using only monocular bronchoscopic video. Clinically significant because it preserves physician decision-making authority while automating the continuous manipulation task most subject to operator fatigue and variability.
4. Competitive Landscape
Intuitive Surgical (Ion). Sunnyvale, CA. Revenue exceeds $8 billion annually across the da Vinci and Ion product lines. Ion uses shape-sensing fiber optic technology for real-time catheter localization without electromagnetic fields. FDA-cleared in 2019. In a multicenter study of 241 patients, Ion achieved diagnostic yield of 81.7% (Fielding et al., Chest, 2022). Key limitation: fully physician-controlled; the shape-sensing fiber provides positioning data but does not automate navigation decisions.
Johnson & Johnson (Monarch). Via Auris Health acquisition ($3.4 billion, 2019). Monarch Platform uses electromagnetic navigation combined with a controller-based interface. FDA-cleared in 2018. The BENEFIT study reported diagnostic yield of 82.0% across 1,253 procedures at 27 sites (Agrawal et al., Lancet Respiratory Medicine, 2023). Key limitation: electromagnetic tracking provides real-time position feedback but does not reduce the physician steering burden.
Noah Medical (Galaxy). San Carlos, CA. Raised $350 million total, including $150 million Series B. Galaxy integrates cone-beam CT imaging directly into the bronchoscopy platform, providing real-time 3D confirmation of tool-in-lesion position. Used in over 10,000 procedures across 180+ hospitals. Published diagnostic yield of 84.6% with cone-beam CT confirmation (Rivera et al., 2023). Key limitation: Galaxy’s innovation is in imaging confirmation, not navigation automation.
No commercial entity offers autonomous navigation for robotic bronchoscopy. All three FDA-cleared platforms are teleoperated systems that require continuous physician input for catheter steering. The academic groups publishing AI navigation results (Zhejiang University, Shanghai Jiao Tong University, Harvard/BWH, Harbin Institute of Technology) are not hardware manufacturers, and the hardware manufacturers have not published autonomous navigation capabilities. This separation between the AI navigation research community and the medical device industry defines the commercial opportunity.
5. Addressable Scope
Bottom-up calculation (US robotic bronchoscopy procedures)
- Annual bronchoscopy procedures (US): approximately 1.6 million (SkyQuest, 2025)
- Diagnostic procedures for peripheral pulmonary lesions: approximately 250,000
- Current robotic bronchoscopy adoption rate: approximately 15%, yielding 37,500 robotic-assisted procedures annually
- Projected robotic-assisted procedure volume by 2030 (LDCT screening expansion): 100,000 to 150,000 annually
- Per-procedure autonomous navigation software license: $2,000 to $5,000
- Estimated US addressable revenue at full penetration: $200M to $500M annually
Top-down cross-check
The global robotic-assisted bronchoscopy market was valued at $750 million in 2024 and is projected to reach $2.6 billion by 2033 at 17.2% CAGR (DataIntelo, 2025). An alternative estimate projects $2.85 billion by 2030 at 10.9% CAGR (Verified Market Reports, 2025). The broader bronchoscopy market is projected to reach $6.82 billion by 2034 (Precedence Research, 2025). Software and AI represent an estimated 15 to 25% of robotic system value, yielding $400 million to $650 million in annual software revenue by 2033. This is consistent with the bottom-up per-procedure estimate.
Serviceable available market
Initial deployment constrained to academic medical centers and high-volume community programs with existing robotic bronchoscopy platforms (estimated 500+ institutions in the US). At 200 procedures per institution annually with a $3,000 per-procedure software license: 500 institutions × 200 procedures × $3,000 = $300M initial SAM. Expansion follows as autonomous navigation enables lower-volume centers without specialist interventional pulmonologists to offer robotic bronchoscopy for the first time.
6. Research Gaps and Opportunity
Three specific gaps separate published research prototypes from a deployable autonomous navigation product. Each gap maps to a distinct capability requirement.
Gap 1: Integration with FDA-cleared hardware platforms
All five published research systems use custom-built or laboratory bronchoscope platforms. No group has demonstrated autonomous navigation on an Ion, Monarch, or Galaxy system. The commercial opportunity requires developing a software module that interfaces with the control APIs of existing FDA-cleared hardware, translating RL navigation commands into the specific actuation signals for each platform. This integration challenge is primarily software engineering, not fundamental research: the RL algorithms are validated, and the hardware platforms accept external control inputs through documented interfaces.
Gap 2: Clinical validation in human patients
The strongest existing evidence comes from live porcine models (Zhang et al., 2024; Liu et al., 2025; Wu et al., 2026) and an ex vivo study with patient-derived airway anatomy (Wu et al., 2026). No autonomous bronchoscope navigation system has been tested in a human clinical trial. Regulatory clearance requires a prospective study demonstrating non-inferiority to physician-controlled navigation in diagnostic yield, safety (pneumothorax rate, bleeding), and procedure time.
Gap 3: Manufacturing of a productized autonomous navigation module
The transition from research prototype to deployable product requires: a ruggedized compute module that runs RL inference in real time (latency under 50ms for continuous catheter control), integration with hospital PACS for preoperative CT loading, a user interface that displays the autonomous navigation plan and allows physician override at any bifurcation point, and cybersecurity architecture meeting FDA premarket guidance for medical device software. The compute module must fit within the physical and electrical constraints of existing robotic bronchoscopy consoles.
Research thesis: No academic lab will close all three gaps because they require manufacturing capability, regulatory strategy, and clinical trial infrastructure that fall outside the scope of robotics research. The lab that published the navigation algorithm does not build medical devices. The medical device manufacturer that builds robotic bronchoscopy hardware has not published autonomous navigation research. This integration gap is the commercial opportunity.
7. Comparable Funded Projects
| Source | PI / Entity | Amount | Focus |
|---|---|---|---|
| NIH NIBIB (R21) | R21EB035832 | ~$275K | Autonomous endoscope navigation using reinforcement learning |
| NIH NIBIB (R21) | R21EB037440 | ~$275K | AI-guided bronchoscopic navigation for peripheral lung lesions |
| ARPA-H | D24AC00415 | Undisclosed | Advanced autonomous surgical and diagnostic robotics |
| NSF CAREER | 2144348 | ~$500K / 5yr | Foundations of autonomous medical robot navigation |
| Intuitive Surgical | Internal R&D | >$500M/yr total | Robotic-assisted surgery platforms including Ion bronchoscopy |
| Noah Medical | Series B | $150M | Galaxy robotic bronchoscopy platform with cone-beam CT |
These awards demonstrate sustained government and industry investment in autonomous medical navigation. NIH NIBIB alone has funded multiple R21 exploratory grants specifically targeting autonomous endoscope and bronchoscope navigation with RL. The combined industry investment in robotic bronchoscopy hardware exceeds $4 billion, creating a massive installed base of platforms that lack autonomous navigation software.
8. Opportunity Assessment
TRL evidence chain
TRL 4 (system validated in relevant environment). Zhang et al. (2024) demonstrated AI-assisted navigation in live porcine lungs (Nature Communications). Liu et al. (2025) demonstrated CT-free AI-driven bronchoscopic search with 5G remote operation at 1,500 km in a live porcine model (Science Robotics). Wu et al. (2026) demonstrated pure-vision autonomous navigation to eighth-generation airways in ex vivo and in vivo porcine models. Banach et al. (2025) validated conditional autonomy in transbronchial interventions (IEEE TBME). All systems were tested in environments with relevant physiological conditions (live tissue, mucus, respiratory motion, anatomical variability), establishing TRL 4.
Top 3 technical risks
Navigation accuracy degradation in diseased airways
Mitigation: Domain randomization during RL training, incorporating simulated pathological airway deformations generated from CT scans of diseased patients. The Long-Short Term Agents framework (Wu et al., 2026) already handles anatomically ambiguous bifurcations through its world-model critic, providing an architectural foundation for pathological anatomy handling.
Go/no-go at Month 12: If autonomous navigation success rate in simulated diseased airways drops below 70% of the rate in normal airways, increase training data augmentation with pathological cases before proceeding to clinical validation.
ModerateReal-time inference latency on embedded compute
Mitigation: Model distillation and quantization (INT8/FP16) targeting NVIDIA Jetson Orin or equivalent medical-grade compute platforms. BronchoCopilot’s attention-based architecture (Zhao et al., 2024) is specifically designed for efficient latent representation, enabling inference optimization.
Go/no-go at Month 9: If inference latency on the target embedded platform exceeds 100ms at the required accuracy threshold, redesign the network architecture for lower computational complexity.
ModerateRegulatory pathway uncertainty for autonomous medical device software
Mitigation: Early FDA pre-submission (Q-Sub) meeting to establish classification strategy and performance testing requirements. The conditional autonomy architecture (Banach et al., 2025), where the physician retains bifurcation-level decision authority, aligns with FDA’s “human in the loop” framework for AI-enabled devices and may face lower regulatory burden than fully autonomous operation.
Go/no-go at Month 6: If FDA pre-submission feedback indicates De Novo classification is required (rather than 510(k)), adjust timeline by 12 to 18 months.
HighRegulatory pathway
510(k) clearance as a software module/accessory to existing FDA-cleared robotic bronchoscopy platforms (Ion, Monarch, or Galaxy as predicate devices). The autonomous navigation module would be classified as a Class II medical device software function. Estimated timeline: 6 months for pre-submission meeting, 12 to 18 months for bench and clinical testing, 6 to 12 months for FDA review. Total: 24 to 36 months to clearance. The first autonomous navigation module cleared by FDA establishes the predicate device for all subsequent 510(k) submissions, giving the first mover a 24 to 36 month exclusivity window.
9. Team Capabilities
Successful pursuit of this research direction requires three intersecting capabilities. HHA’s team provides coverage across all three:
Hass Dhia
MS Biomedical Sciences with medical school background (anatomy, physiology, pharmacology). AI infrastructure architect with production systems at scale. Provides the biomedical domain expertise required for pulmonary anatomy modeling (bronchial tree branching patterns through 23 generations, airway diameter variation from 15mm trachea to sub-millimeter terminal bronchioles), respiratory physiology (mucosal surface dynamics, respiratory motion artifacts, mucus clearance patterns), and clinical workflow integration. Leads experimental methodology, clinical trial design for FDA regulatory submissions, and sensor fusion architecture for integrating endoscopic video with preoperative CT registration.
Haedar Hadi
MS Computer Science (Boston University). Specializes in ML model development, reinforcement learning architectures, and evaluation methodology. Provides the machine learning expertise required for autonomous airway navigation: deep RL architectures for continuous control in visually complex, deformable environments; sim-to-real transfer from CT-derived virtual bronchial trees to physical bronchoscope deployment on FDA-cleared hardware; multimodal fusion (endoscopic video, proprioceptive catheter state, preoperative CT) for robust state estimation. Leads navigation controller development, model distillation for embedded inference, and safety-constrained policy optimization with formal verification of collision avoidance bounds.
Ahmed Dhia
Senior manufacturing engineer with deep expertise in design for manufacturability (DFM), production scaling, and quality systems. Provides the manufacturing engineering capability for the autonomous navigation compute module: embedded GPU integration within existing robotic bronchoscopy console form factors, thermal management for continuous compute loads in an operating room environment, electromagnetic compatibility (EMC) testing per IEC 60601-1-2, and cybersecurity architecture per FDA premarket guidance. Quality systems (ISO 13485) for software as a medical device (SaMD). Production scaling from prototype to fleet deployment across 500+ clinical sites, including software update distribution, remote monitoring, and field service infrastructure.
This is the precise capability gap where most funded surgical robotics AI research stalls: the transition from a research prototype running on a laboratory workstation to a regulatory-compliant, hospital-deployable product that operates reliably across diverse clinical environments and patient anatomies. Ahmed’s background in production scaling and quality systems directly addresses Gap 3 (manufacturing of a productized autonomous navigation module), the single highest-risk technical barrier identified in this assessment.
10. Recommended Next Steps
Target funding programs
| Program | Mechanism | Range | Fit |
|---|---|---|---|
| NIH NIBIB | R01 / R21 | $250K–$500K/yr | Biomedical imaging + autonomous navigation; AI-guided interventional pulmonology systems |
| NCI | R01 / R21 | $250K–$500K/yr | Early lung cancer detection; technology to improve diagnostic yield for peripheral pulmonary lesions |
| ARPA-H Open BAA | Performer agreement | $1M–$10M | High-risk, high-reward health technology; autonomous diagnostic robotics fits “scalable solutions” thrust |
| NSF CBET | CAREER / R01-equiv | $300K–$500K/yr | Bioengineering and transport systems; RL-based autonomous navigation in deformable anatomical environments |
| NCI SBIR/STTR | Phase I / Phase II | $300K / $2M | Cancer diagnostic technology; software for improved lung cancer biopsy yield |
| Schmidt Sciences | Open RFP | $1M–$5M+ | Embodied AI for real-world applications; convergence of RL + surgical robotics + clinical autonomy |
Estimated total funding range: $1.5M–$6M over 24–36 months for Phase 1 (autonomous navigation validation on FDA-cleared hardware + manufacturing feasibility + FDA pre-submission).
24-month milestone timeline
- M1–3 Literature review completion. CT bronchography dataset acquisition for airway phantom generation. RL simulation environment design based on patient-derived bronchial tree anatomies. FDA pre-submission meeting preparation.
- M4–8 RL navigation controller v1 trained on simulated bronchial anatomies (healthy + diseased). DFM analysis for embedded compute module integration with Ion/Monarch/Galaxy consoles. Pre-submission meeting with CDRH to establish 510(k) classification strategy.
- M9–14 Sim-to-real transfer validation on FDA-cleared hardware using airway phantoms. Model distillation and INT8/FP16 quantization for embedded inference (target: under 50ms latency on NVIDIA Jetson Orin). Embedded compute module prototype (v1) with thermal and EMC characterization.
- M15–20 Preclinical validation in large-animal model (porcine) on FDA-cleared hardware. Software verification and validation (V&V) documentation. ISO 13485 quality system gap analysis and remediation. Physician UI development (navigation plan display, override controls).
- M21–24 Publication of navigation controller performance results (target: peer-reviewed journal). 510(k) submission package preparation. First-in-human study protocol design (IRB submission). Phase 2 funding application (multicenter clinical validation + manufacturing qualification).